Barcelona-based biotech company Zymvol Biomodeling, specializing in tailor-made enzymes, has secured €3 million in a seed funding round. Led by Faber Ventures and supported by Elaia Partners and Übermorgen Ventures, the investment will help the startup enhance its experimental laboratory.
- Founded in 2017 by Emanuele Monza, Maria Fátima Lucas, and Víctor Gil, Zymvol Biomodeling specializes in computational enzyme discovery and design.
- The company uses advanced simulations to develop custom enzymatic solutions for industrial applications. This enhances enzyme engineering efficiency and reduces the need for trial-and-error experimentation. Zymvol has completed over 100 projects for clients such as Axplora, Medichem, and Sanofi.
- The startup reports that its advanced computer simulations replicate experimental conditions with over 90% accuracy, reducing development time by 50%, lab work by 90%, and boosting success rates in enzyme discovery and design campaigns to over 75%.
"Enzymes are tiny chemical factories that are responsible for all transformations in Nature. We’re harnessing their power to deliver clean, sustainable chemical processes to companies striving to improve their products and operations—paving the way for a better world," claims Maria Fátima Lucas, CEO at Zymvol.
Details of the deal
- The seed round was led by Faber Ventures, a Lisbon-based VC that launched its €60 million deep tech fund, Faber Tech III, last year. The fund invests in pre-seed and seed-stage startups focused on vertical AI, AI governance, robotics, computational biology and chemistry, data infrastructure, and novel computation.
"Biocatalysis presents significant challenges —enzyme discovery and engineering remain complex, costly, and time-consuming. Zymvol’s advanced computational solutions go beyond improving efficiency; they strengthen industrial resilience, drive sustainable innovation, and shape the future of global production,” Partner at Faber, Sofia Santos, commented.
- The investemnt also saw participation from Paris-based VC Elaia Partners and Übermorgen Ventures.
- The €3 million seed funding will be used to upgrade Zymvol's experimental lab, expand its computational technology, strengthen its sales and marketing efforts, and launch its first custom enzyme kits.
